Table 4 The sensitivity and specificity of DMRTA2 by different clinical characteristics in the aggregate set
Clinical characteristics | DMRTA2-positive | Bladder cancer | Sensitivity(95%CI) | DMRTA2-negative | Non-cancer disease | Specificity (95%CI) |
|---|---|---|---|---|---|---|
Total | 179 | 216 | 82.9% (77.0–87.5%) | 468 | 506 | 92.5% (89.7–94.6%) |
Age | ||||||
  < 60 | 29 | 44 | 65.9% (50.0–79.1%) | 218 | 233 | 93.6% (89.4–96.2%) |
 60 ~ 69 | 63 | 74 | 85.1% (74.5–92.0%) | 156 | 169 | 92.3% (86.9–95.7%) |
 70 ~ 79 | 62 | 68 | 91.2% (81.1–96.3%) | 76 | 85 | 89.4% (80.4–94.7%) |
  ≥ 80 | 25 | 30 | 83.3% (64.5–93.7%) | 18 | 19 | 94.7% (71.9–99.7%) |
Sex | ||||||
 Male | 152 | 179 | 84.9% (78.6–89.7%) | 281 | 306 | 91.8% (88.0–94.5%) |
 Female | 30 | 37 | 81.1% (64.3–91.4%) | 187 | 200 | 93.5% (88.9–96.3%) |
Grade | ||||||
 Low | 60 | 84 | 71.4% (60.4–80.5%) | 0 | 0 | NA |
 High | 106 | 112 | 94.6% (88.2–97.8%) | 0 | 0 | NA |
 NA | 16 | 20 | 80% (55.7–93.4%) | 0 | 0 | NA |
Stage | ||||||
 Ta | 34 | 54 | 63% (48.7–75.4%) | 0 | 0 | NA |
 T1 | 66 | 73 | 90.4% (80.7–95.7%) | 0 | 0 | NA |
 T2 | 38 | 40 | 95.0% (81.8–99.1%) | 0 | 0 | NA |
 T3 | 9 | 11 | 81.8% (47.8–96.8%) | 0 | 0 | NA |
 T4 | 9 | 11 | 81.8% (47.8–96.8%) | 0 | 0 | NA |